This mechanism promoted PD-L1 expression in a mouse model of renal cell carcinoma (RCC) and EHBP1L1 inhibition resulted in increased CTL activity and improved response to ICBT [73]. The gene discussed is EHBP1L1; the disease is renal cell carcinoma.